Non alcoholic fatty liver. Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention 1: Control group: The placebo will be taken once a day with lunch, which is quite similar in color and size to the main medicine. Intervention 2: Intervention group: Patients in the astax
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
8 Years to 18 Years
Inclusion criteria
Inclusion criteria: Children with non- alcoholic fatty liver disease Age between 8-18 years old Elevation of liver enzyme more than 40 Unit/Litre Evidence of fatty liver in sonography
Exclusion criteria
Exclusion criteria: Diagnosis of liver disease other than NAFLD such as : Viral hepatitis,Autoimmune hepatitis, Diabetes, Hemochromatosis, Cirrhosis, Infectious disease, Hypothyroidism Consumption of drugs that effect on liver enzyme during last two months Alcohol consumption Discontinuing the study by the patient or his/her family
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum level of Alanine aminotransferase. Timepoint: Eight weeks after treatment initiation with placebo and astaxanthin. Method of measurement: Quantitative measurement of liver transaminase.;Serum level of Aspartate aminotransferase. Timepoint: Eight weeks after treatment initiation with placebo and astaxanthin. Method of measurement: Quantitative measurement of liver transaminase.;Serum levels of cytokeratin 18. Timepoint: Eight weeks after treatment initiation with placebo and astaxanthin. Method of measurement: Eliza method. | — |
Secondary
| Measure | Time frame |
|---|---|
| Body fat mass. Timepoint: Eight weeks after treatment initiation with placebo and astaxanthin. Method of measurement: Inbody 270 body composition measuring device.;Lean body mass. Timepoint: Eight weeks after treatment initiation with placebo and astaxanthin. Method of measurement: Inbody 270 body composition measuring device.;Body mass index. Timepoint: Eight weeks after treatment initiation with placebo and astaxanthin. Method of measurement: Measurement of height and weight and ratio of weight to square of height.;Waist circumference. Timepoint: Eight weeks after treatment initiation with placebo and astaxanthin. Method of measurement: Measurement with meters.;Hip circumference. Timepoint: Eight weeks after treatment initiation with placebo and astaxanthin. Method of measurement: Measurement with meters.;Weight. Timepoint: Eight weeks after treatment initiation with placebo and astaxanthin. Method of measurement: Measurement with scales.;Height. Timepoint: Eight weeks after treatment initiation with placebo and astaxanthin. Method of measurement: Measurement with meters. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMajid Khademian
Esfahan University of Medical Sciences
Outcome results
None listed